Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.

Acelyrin, Inc.

ACELYRIN, INC.  (Nasdaq: SLRN) is a Los Angeles area-based late-stage clinical biopharma company – with additional operations in the San Francisco Bay area – focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising product candidates.

ACELYRIN is embedding a corporate culture of Courageous Caring™ -- placing patients first and embracing the concept that all of us are better than any one of us -- as we seek to addresses the most basic human needs: to live a productive life free from diseases.

RTW Investments

Samsara BioCapital

Westlake Village BioPartners

Cowen Healthcare Investments

Decheng Capital

Surveyor Capital

Tybourne Capital Management

Marshall Wace

Matrix Capital Management

OrbiMed

Ischyros New York

Access Biotechnology

venBio Partners

ACELYRIN, INC.

ACELYRIN management will be participating in investor conferences hosted by Jefferies, Piper Sandler and Evercore ISI this month. Live webcasts of our fireside chats will be available via the “Events” section of the Company’s website. Full details below.

Today, ACELYRIN reported financial results for the third quarter of 2023 and highlighted additional corporate updates and milestones. CEO Dr. Shao-Lee Lin, MD, PhD shares more about these updates below. Read the full press release here. https://lnkd.in/gJtWrsTC

We are excited to share the appointment of Patricia Turney as Chief Technical Operations Officer. Patricia will join our Senior Leadership Team to oversee technical operations, CMC regulatory, corporate quality and facilities. With her impressive background and eager mindset, we're thrilled to welcome Patricia to our team during this important time for ACELYRIN. Welcome, Patricia! Read the full release here. https://lnkd.in/ecRzgUwu

We are thrilled to share that ACELYRIN has opened our office in #SanFrancisco! Team members were invited to connect and celebrate in our office space this week. We're excited for the growth and expansion for our team in the Bay Area.

We look forward to hosting a conference call on Tuesday, November 7 at 4:30 p.m. ET to review our Q3 2023 financial results and provide a corporate update. A live webcast of the conference call will be available on the ‘Events’ section of our website. www.acelyrin.com/events

It was great to catch up with clinicians and industry partners, as well as be a sponsor at the recent #Thyroid Eye Disease (TED) Patient Forum, hosted by Kahana Oculoplastic & Orbital Surgery and the American Academy of Adult and Pediatric Medicine. The forum hosted physicians, patients, families, and advocates alike to discuss aspects of diagnosis and treatment of TED.

Our team has been enjoying our visit to Berlin for #EADV23! We have appreciated the opportunity to connect with other researchers, clinicians, and industry professionals in our focus to develop new treatment options for #HidradenitisSuppurativa. Come visit us at booth K39 to learn more.

We're excited to sponsor the Hidradenitis Suppurativa Foundation, Inc. 2023 Symposium on Hidradenitis Suppurativa Advances (SHSA) this weekend. This important symposium fosters worldwide research by scientists and physicians devoted to studying #HidradenitisSuppurativa, in order to deliver more effective forms of treatment and improve the lives of patients affected by HS. Learn more about the event below.

We are thrilled to share the appointment of Shephard Mpofu as our Senior Vice President of Development to lead clinical development and translational sciences. We look forward to adding his experience having previously led the development of secukinumab to our Senior Leadership Team as we advance transformative medicines for patients. Read more about Dr. Mpofu's impressive career in drug development here: https://lnkd.in/gJKdv2Q5

Today we announced top-line results from Part B of our Phase 2b/3 trial of izokibep in Hidradenitis Suppurativa. Thank you to the patients and clinicians in this trial, without whom we would not be able to continue to learn about how best to treat this debilitating disease. Although the overall study did not meet statistical significance, the results further support our ongoing evaluations of 160 mg QW dosing in HS, as well as for additional indications, including uveitis and PsA, the largest potential indication for izokibep. 
https://lnkd.in/gcnqgRkN
#SLRN

	Dec '21	Dec '22	Dec '23
net income	-41.84M -	-64.77M 54.81%	-381.64M 489.21%
depreciation and amortization			115K -
deferred income tax
stock based compensation	233K -	4.05M 1,639.06%	47.32M 1,067.77%
change in working capital	11.63M -	-67K 100.58%	52.08M 77,829.85%
accounts receivables
inventory
accounts payables	1.12M -	3.78M 237.44%	34.44M 812.16%
other working capital	10.51M -	-3.84M 136.57%	1.69M 144.00%
other non cash items	25M -	-733K 102.93%	133.21M 18,273.26%
net cash provided by operating activities	-4.98M -	-61.52M 1,135.59%	-169.71M 175.85%
investments in property plant and equipment	-25M -		-12.29M -
acquisitions net		-83K -	10.01M 12,156.63%
purchases of investments		-175.97M -	-956.51M 443.57%
sales maturities of investments		128.18M -	511.06M 298.70%
other investing activites			-455.46M -
net cash used for investing activites	-25M -	-47.87M 91.50%	-447.74M 835.26%
debt repayment
common stock issued			574.13M -
common stock repurchased			-8.32M -
dividends paid
other financing activites		274.26M -	-8.32M 103.04%
net cash used provided by financing activities	124.72M -	274.26M 119.90%	568.44M 107.26%
effect of forex changes on cash
net change in cash	94.74M -	164.87M 74.02%	-49.01M 129.73%
cash at beginning of period	7.50M -	102.24M 1,263.04%	267.11M 161.25%
cash at end of period	102.24M -	267.11M 161.25%	218.10M 18.35%
operating cash flow	-4.98M -	-61.52M 1,135.59%	-169.71M 175.85%
capital expenditure	-25M -		-12.29M -
free cash flow	-29.98M -	-61.52M 105.21%	-182.00M 195.84%

COM:ACELYRIN

Acelyrin, Inc.

Last Close

4.33

21/11 21:01

Market Cap

508.01M

Beta: -

Volume Today

332.61K

Avg: -

Preview